公开(公告)号：US20250034162A1

公开(公告)日：2025-01-30

申请号：US18887703

申请日：2024-09-17

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Rohan Rej ,  Changwei Wang ,  Mi Wang ,  Jianfeng Lu ,  Chao-Yie Yang ,  Ester Fernandez-Salas ,  Jeanne Stuckey

IPC: C07D491/22 ,  A61K45/06 ,  A61P35/00 ,  C07D471/22 ,  C07D487/04 ,  C07D487/14 ,  C07D495/14 ,  C07D495/22 ,  C07D498/22 ,  C07D513/22 ,  C07F9/6561

Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.

公开(公告)号：US20240190880A1

公开(公告)日：2024-06-13

申请号：US18279236

申请日：2022-03-04

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Zhixiang Chen ,  Rohan Rej ,  Dimin Wu ,  Jianfeng Lu ,  Biao Hu ,  Mingliang Wang ,  Ranjan Kumar Acharyya

IPC: C07D487/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  C07D519/00

Abstract: The present disclosure relates to compounds of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X, J, Y, Z, n, and B 1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating preventing a condition or disorder responsive to the degradation of estrogen receptor protein (e.g., cancer).

公开(公告)号：US20220227778A1

公开(公告)日：2022-07-21

申请号：US16971472

申请日：2020-07-16

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Rohan Rej ,  Changwei Wang ,  Mi Wang ,  Jianfeng Lu ,  Chao-Yie Yang ,  Ester Fernandez-Salas ,  Jeanne Stuckey

IPC: C07D491/22 ,  C07D487/14 ,  C07D471/22 ,  C07D495/14 ,  C07D495/22 ,  C07D513/22 ,  C07D487/04 ,  C07F9/6561 ,  C07D498/22 ,  A61P35/00 ,  A61K45/06

Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.

公开(公告)号：US10759808B2

公开(公告)日：2020-09-01

申请号：US16091544

申请日：2017-04-06

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Yangbing Li ,  Angelo Aguilar ,  Bing Zhou ,  Jiantao Hu ,  Fuming Xu ,  Chong Qin ,  Yang Hu ,  Weiguo Xiang ,  Rohan Rej ,  Jiuling Yang ,  Xin Han ,  Longchuan Bai ,  Chao-Yie Yang

IPC: C07D401/04 ,  C07D487/10 ,  C07D401/14 ,  C07D487/04 ,  C07D495/14

Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.